Literature DB >> 28893712

Single-Session Percutaneous Endovascular Mesocaval Shunt Creation and Balloon-Occluded Retrograde Transvenous Obliteration for the Treatment of Gastric Varices.

Ravi Nara Srinivasa1, Bill S Majdalany1, Jeffrey Forris Beecham Chick2, J Matthew Meadows1, Jordan Bruce Fenlon3, Charles Brewerton3, Wael E Saad1.   

Abstract

In the setting of portal hypertension, the body responds by creating portosystemic venous shunts, which may lead to the development of varices. Endoscopic treatment of these varices is often warranted to prevent catastrophic bleeding. During the course of variceal treatment, 1 or more portosystemic shunts may be sacrificed, which may acutely exacerbate portal hypertension and reduce systemic venous return. This report describes percutaneous creation of a mesocaval shunt and balloon-occluded retrograde transvenous obliteration (BRTO) in a patient with cavernous transformation of the portal vein. The patient had previously undergone an unsuccessful attempt at transjugular intrahepatic portosystemic shunt (TIPS) creation with postoperative bleeding requiring splenectomy. As TIPS was not feasible, creation of a percutaneous mesocaval shunt provided an alternate pathway for portosystemic decompression, facilitating safe treatment of gastric varices with BRTO via a gastrorenal shunt. These procedures were performed simultaneously to reduce the risk of variceal bleeding from acute changes in portal venous pressures and redirect blood flow through the shunt to maintain patency. This is the first reported case of combined mesocaval shunt placement and BRTO in a single session.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28893712     DOI: 10.1016/j.avsg.2017.08.040

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  1 in total

1.  Transcatheter Embolization of Renal-Splenic Shunt to Treat Hematemesis.

Authors:  Neema Jamshidi; Stephen T Kee
Journal:  Cardiovasc Intervent Radiol       Date:  2020-07-24       Impact factor: 2.797

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.